Crescent Biopharma (CBIO)
NASDAQ:CBIO
Want to see CBIO full AI Analyst Report?
Total Valuation
Crescent Biopharma has a market cap or net worth of $550.61M. The enterprise value is $362.99M.
Market Cap$550.61M
Enterprise Value$362.99M
Share Statistics
Crescent Biopharma has 27,571,936 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27,571,936
Owned by Insiders12.51%
Owned by Institutions58.78%
Financial Efficiency
Crescent Biopharma’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -74.58%.
Return on Equity (ROE)-0.76
Return on Assets (ROA)-0.64
Return on Invested Capital (ROIC)-74.58%
Return on Capital Employed (ROCE)-0.75
Revenue Per Employee264.49K
Profits Per Employee-3.66M
Employee Count41
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Crescent Biopharma is ―. Crescent Biopharma’s PEG ratio is -0.00084.
PE Ratio―
PS Ratio11.39
PB Ratio0.61
Price to Fair Value0.61
Price to FCF-1.70
Price to Operating Cash Flow-8.05
PEG Ratio-0.00084
Income Statement
In the last 12 months, Crescent Biopharma had revenue of 10.84M and earned -153.94M in profits. Earnings per share was -14.78.
Revenue10.84M
Gross Profit10.84M
Operating Income-152.63M
Pretax Income-151.94M
Net Income-153.94M
EBITDA-149.67M
Earnings Per Share (EPS)-14.78
Cash Flow
In the last 12 months, operating cash flow was -75.36M and capital expenditures -73.07M, giving a free cash flow of -148.43M billion.
Operating Cash Flow-75.36M
Free Cash Flow-148.43M
Free Cash Flow per Share-5.38
Dividends & Yields
Crescent Biopharma pays an annual dividend of $0.24, resulting in a dividend yield of ―
Dividend Per Share$0.24
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.10
52-Week Price Change-23.13%
50-Day Moving Average13.36
200-Day Moving Average12.90
Relative Strength Index (RSI)73.91
Average Volume (3m)145.41K
Important Dates
Crescent Biopharma upcoming earnings date is Jul 30, 2026, After Close (Confirmed).
Last Earnings DateApr 29, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Crescent Biopharma as a current ratio of 6.56, with Debt / Equity ratio of 0.84%
Current Ratio6.56
Quick Ratio6.56
Debt to Market Cap0.01
Net Debt to EBITDA1.41
Interest Coverage Ratio-69.85
Taxes
In the past 12 months, Crescent Biopharma has paid 2.00M in taxes.
Income Tax2.00M
Effective Tax Rate-0.01
Enterprise Valuation
Crescent Biopharma EV to EBITDA ratio is 0.59, with an EV/FCF ratio of 1.22.
EV to Sales-8.12
EV to EBITDA0.59
EV to Free Cash Flow1.22
EV to Operating Cash Flow1.23
Balance Sheet
Crescent Biopharma has $189.16M in cash and marketable securities with $1.54M in debt, giving a net cash position of $187.62M billion.
Cash & Marketable Securities$189.16M
Total Debt$1.54M
Net Cash$187.62M
Net Cash Per Share$6.80
Tangible Book Value Per Share$19.49
Margins
Gross margin is 100.00%, with operating margin of -1407.52%, and net profit margin of -1419.61%.
Gross Margin100.00%
Operating Margin-1407.52%
Pretax Margin-1401.16%
Net Profit Margin-1419.61%
EBITDA Margin-1380.24%
EBIT Margin-1381.01%
Analyst Forecast
The average price target for Crescent Biopharma is $29.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$29.50
Price Target Upside38.63% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast72.70%